Trading- und Aktien-Chat Forum: Community User: ÄffchenNotToGo

Urlaub…. Ich habe es geschafft ab heute 23 Tage frei. Es war heftig fast das gesamte bisherige Jahr durchzuarbeiten. Jetzt geht es dann endlich bald los. Seit Anfang Mai bin Ich am planen. Dienstag geht’s mit dem Zug 🚄🚄🚄von Passau über Regensburg, Nürnberg, Würzburg,Hanau zum Flughafen Frankfurt Fernbahnhof. Mit dem Shuttlebus vom T1 zum Steigenberger Airport Hotel .Dort habe ich ein Business Single Zimmer ( 17 Quadratmeter) reserviert. Am Mittwoch dann Mittag mit der Singapore Airlines in nur 12 Std nach Singapur von dort weiter nach Perth nochmals 6 Std. Gruß Martin 🤞🤞👀👀

Urlaub…. Ich habe es geschafft ab heute 23 Tage frei. Es war heftig fast das gesamte bisherige Jahr durchzuarbeiten. Jetzt geht es dann endlich bald los. Seit Anfang Mai bin Ich am planen. Dienstag geht’s mit dem Zug 🚄🚄🚄von Passau über Regensburg, Nürnberg, Würzburg,Hanau zum Flughafen Frankfurt Fernbahnhof. Mit dem Shuttlebus vom T1 zum Steigenberger Airport Hotel .Dort habe ich ein Business Single Zimmer ( 17 Quadratmeter) reserviert. Am Mittwoch dann Mittag mit der Singapore Airlines in nur 12 Std nach Singapur von dort weiter nach Perth nochmals 6 Std. Gruß Martin 🤞🤞👀👀

Urlaub…. Ich habe es geschafft ab heute 23 Tage frei. Es war heftig fast das gesamte bisherige Jahr durchzuarbeiten. Jetzt geht es dann endlich bald los. Seit Anfang Mai bin Ich am planen. Dienstag geht’s mit dem Zug 🚄🚄🚄von Passau über Regensburg, Nürnberg, Würzburg,Hanau zum Flughafen Frankfurt Fernbahnhof. Mit dem Shuttlebus vom T1 zum Steigenberger Airport Hotel .Dort habe ich ein Business Single Zimmer ( 17 Quadratmeter) reserviert. Am Mittwoch dann Mittag mit der Singapore Airlines in nur 12 Std nach Singapur von dort weiter nach Perth nochmals 6 Std. Gruß Martin 🤞🤞👀👀

Canadian National Railway reported a rise in third-quarter profit and revenue thanks to higher freight volumes transported. The Canadian railroad on Friday posted higher net income of 1.14 billion Canadian dollars ($815 million), or C$1.83 a share, up from C$1.09 billion, or C$1.72 a share, in the comparable quarter a year earlier. Adjusted earnings were C$1.83 a share, coming in ahead of the C$1.77 a share that analysts expected for the period, according to a FactSet poll. Total revenue rose in the quarter, reaching C$4.17 billion from C$4.11 billion a year earlier, just ahead of Wall Street expectations of a rise to C$4.16 billion. Freight revenue rose to C$3.99 billion from C$3.92 billion. CN Rail operates a nearly 20,000-mile rail network and related transportation services, connecting Canada's eastern and western coasts with the U.S. Midwest and the U.S. Gulf Coast. On the operations side, gross ton miles increased 1% to 111.9 billion and revenue ton miles also rose 1% to 57.19 billion. GTM represents the total weight of a train multiplied by the distance traveled in miles, while RTM, a financial metric, is the weight of revenue-generating freight multiplied by the distance. Operating ratio, which measures efficiency, was 61.4%, down by 170 basis points from a year earlier. In this metric, a lower ratio indicates better profitability. For the year, Montreal-based CN Rail said it would keep its guidance unchanged, calling for mid- to high-single-digit adjusted earnings-per-share growth. It also said it continues to invest net of about C$3.35 billion in its capital program.. @Ascadian

Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third -Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues Were $993 Million Third -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.841 Billion, an Increase of 20.2 Percent on a Reported Basis, or 19.6 Percent on an Operational Basis; Global Vraylar Net Revenues Were $934 Million; Global Botox Therapeutic Net Revenues Were $985 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $642 Million Third -Quarter Global Net Revenues from the Oncology Portfolio Were $1.682 Billion, a Decrease of 0.3 Percent on a Reported Basis, or 1.3 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $706 Million; Global Venclexta Net Revenues Were $726 Million; Global Elahere Net Revenues Were $170 Million Third -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.193 Billion, a Decrease of 3.7 Percent on a Reported Basis, or 4.2 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $637 Million; Global Juvederm Net Revenues Were $253 Million Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 - $10.58 to $10.61 - $10.65, which Includes an Unfavorable Impact of $2.05 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2025 Announces 2026 Dividend Increase of 5.5 Percent, Beginning with Dividend Payable in February 2026